45th week of 2009 patent applcation highlights part 37 |
Patent application number | Title | Published |
20090275507 | CONTRACEPTIVE COMPOSITION - The present invention relates to a contraceptive composition including an effective amount of a dendrimer compound including one or more naphthyl disulphonic acid surface groups, or a pharmaceutically acceptable salt or solvate of the dendrimer compound; and a pharmaceutically acceptable carrier, excipient and/or diluent therefor. The contraceptive composition may also exhibit antimicrobial activity. The invention also relates to a method of selectively reducing or preventing conception in a female animal, including a human, which method includes administering to the animal an effective amount of a contraceptive composition which composition includes an effective amount of a dendrimer compound including one or more naphthyl disulphonic acid surface groups, or a pharmaceutically acceptable salt or solvate of the dendrimer compound; and a pharmaceutically acceptable carrier, excipient and/or diluent therefor. | 2009-11-05 |
20090275508 | USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION - It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. | 2009-11-05 |
20090275509 | METHOD FOR STIMULATING ANGIOGENESIS USING DKK2 AND COMPOSITION COMPRISING THE SAME - The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease. | 2009-11-05 |
20090275510 | Compositions and Methods for Inducing or Inhibiting Activities of Selected Human Cells - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 2009-11-05 |
20090275511 | ANALOGS OF GHRELIN SUBSTITUTED AT THE N-TERMINAL - The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: | 2009-11-05 |
20090275512 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION - The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptide. | 2009-11-05 |
20090275513 | COMPOSITION AND METHOD FOR PREPARING PLASMINOGEN - Disclosed is both a method for preparing a plasminogen and a method for preparing a reversibly inactive acidified plasmin by activating the plasminogen. The prepared plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The prepared plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy. | 2009-11-05 |
20090275514 | USE OF CALMODULIN KINASE II INHIBITORS TO TREAT OR PREVENT HEART MUSCLE INFLAMMATION - Provided are compositions and methods of treating inflammation of the heart of a subject diagnosed with inflammation of the heart, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II, whereby the administration of the inhibitor treats inflammation of the heart in the subject. Also provided are compositions and methods of preventing inflammation of the heart of a subject, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II, whereby the administration of the inhibitor prevents inflammation of the heart in the subject. | 2009-11-05 |
20090275515 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS - Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. | 2009-11-05 |
20090275516 | COMPOUNDS AND METHOD FOR MODULATING INFLAMMATORY REACTIONS - The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products. | 2009-11-05 |
20090275517 | G-CSF POLYPEPTIDES AND USES THEREOF - The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 2009-11-05 |
20090275518 | G-CSF POLYPEPTIDES AND USES THEREOF - The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 2009-11-05 |
20090275519 | Therapeutic peptidomimetic macrocycles - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 2009-11-05 |
20090275520 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE - Various methods of using peptides are provided where the peptides comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. | 2009-11-05 |
20090275521 | Regulation of Microphage Migration Inhibitory Factor (MIF) Activity - The present invention relates to modulating, neutralizing, or inactivating the activity of migration inhibitory factor (MIF). In particularm, the present invention provides methods for modulating, neutralizing, or inactivating MIF activity by complexing MIF with other molecules, preferably a protein, that is capable of associating with MIF. These molecules can be used for treating diseases by the regulation of MIF activity. | 2009-11-05 |
20090275522 | Novel Compounds - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 2009-11-05 |
20090275523 | Spirocyclic nitriles as protease inhibitors - The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments. | 2009-11-05 |
20090275524 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS - The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents | 2009-11-05 |
20090275525 | USE OF A LACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses. | 2009-11-05 |
20090275526 | Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions. | 2009-11-05 |
20090275527 | SKIN AGING TREATMENT COMPRISING PAEONIFLORIN - The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition comprising paeoniflorin may become a very useful skin aging treatments. | 2009-11-05 |
20090275528 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS - The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R | 2009-11-05 |
20090275529 | METHOD FOR IMPROVING CARDIOVASCULAR RISK PROFILE OF COX INHIBITORS - A method of reducing the increased risk of cardiovascular events attendant with the use of COX or selective COX-2 inhibitors including restoring disrupted cholesterol metabolic function engendered by the use of the COX or selective COX-2 inhibitors and reducing the production of foam cells caused thereby. The disrupted cholesterol metabolic function is restored and the production of foam cells is reduced by the step of administering an adenosine A2A receptor agonist having a threshold level of activity of 0.1 μM to a patient using the COX or COX-2 inhibitor. The adenosine A2A receptor agonist is administered orally in amounts sufficient to saturate the A2A receptor and at time intervals sufficient to maintain the restored cholesterol metabolic function. | 2009-11-05 |
20090275530 | Gastric Raft Composition Comprising Preferably Processed Starches For Inducing Satiety - Provided are methods of inducing satiety in an individual using gastric raft compositions and compositions suitable for such methods. The gastric raft compositions may comprise processed starches such as dextrins. Also described are methods of treating diseases characterised by hypoglycaemia, such as glycogen storage disease (GSD), and diabetes. | 2009-11-05 |
20090275531 | Method for producing starch networks and initial products - The invention relates to a method for producing starch networks. The method may include preparing a basic starch and preparing a networking starch. The method may further include manufacturing an initial product including the basic starch and the networking starch, and processing the initial product to yield the starch networks, such that the starch networks are at least partially heterocrystallized. | 2009-11-05 |
20090275532 | COSMETIC COMPOSITION COMPRISING AN OIL - The present invention relates to a cosmetic composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase and at least 15% by weight, relative to the total weight of the composition, of a fatty phase comprising at least one liquid fatty phase having at least one non-volatile fraction, the said liquid fatty phase comprising at least one dry oil chosen from oils with a viscosity of less than or equal to 10 Cps, a surface tension of between 21 and 31 mN/m and an evaporation rate of less than 0.002 mg/cm2/minute, the said dry oil being present in the emulsion in a content ranging from 55% to 100% by weight relative to the total weight of the non-volatile fraction of the liquid fatty phase, the said liquid fatty phase being such that the calculated weight ratio of the liquid fatty phase remaining in the composition after 10 minutes of drying, to the initial liquid fatty phase, ranges from 0.75 to 1. The invention also relates to the use of the said composition for obtaining a uniform makeup and/or a makeup that does not transfer. | 2009-11-05 |
20090275533 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS - Fused bicyclic pyrimidine compounds of formula (I): | 2009-11-05 |
20090275534 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations. | 2009-11-05 |
20090275535 | ANTIVIRAL PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2009-11-05 |
20090275536 | Antibacterial Agents - Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition. | 2009-11-05 |
20090275537 | Certain chemical entities, compositions, and methods - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 2009-11-05 |
20090275538 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS - The present invention relates to Arylmethylidene heterocycles, compositions comprising an Arylmethylidene heterocycle, and methods useful for treating or preventing pain comprising administering an effective amount of an Arylmethylidene heterocycle. The compounds, compositions, and methods of the invention are also useful for treating or preventing inflammation. | 2009-11-05 |
20090275539 | Nuclear Transcription Factors Regulators - The present invention relates to novel compounds that are nuclear transcription factors (NTF) regulators. The present invention also provides methods for treating, preventing and/or reducing inflammation associated diseases by regulating NTF in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as tumoral and infective diseases employing said compounds. | 2009-11-05 |
20090275540 | Pre-Compacted Calcium-Containing Compositions - A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g. tablets. | 2009-11-05 |
20090275541 | Method for treating neurocognitive dysfunction - A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment. Formula I is: | 2009-11-05 |
20090275542 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS - Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms. | 2009-11-05 |
20090275543 | Modified Glycosaminoglycans, Pharmaceutical Compositions and Methods for Oral Delivery Thereof - This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for orally delivering heparin to a subject comprising administering to the subject a pharmaceutically effective amount of a pharmaceutical composition comprising a glycosaminoglycan or derivative thereof covalently linked to a bile acid and (b) a pharmaceutically acceptable carrier. | 2009-11-05 |
20090275544 | Method and kit for reducing the symptoms of peripheral vascular disease - A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof. | 2009-11-05 |
20090275545 | Medicinal targeted local lipolysis - Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue. | 2009-11-05 |
20090275546 | Diagnostic tests and personalized treatment regimes for cancer stem cells - Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime that include receiving metabolic information relating to a cancer stem cell in a patient, determining the patient's personal criteria relevant to the therapeutic regime, and combining the metabolic and personal criteria. Also provided are a diagnostic test for establishing a personalized therapeutic regime for a colon cancer patient and methods of reducing colon cancer stem cells/treating colon cancer. | 2009-11-05 |
20090275547 | METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS - Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase inhibitor. Also disclosed are methods for treating a kinase-affected disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a disclosed organometallic kinase inhibitor. | 2009-11-05 |
20090275548 | COMPOUNDS AND METHODS FOR ACTIVATED THERAPY - Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using sonodynamic and/or photodynamic methods. In particular, photosensitizer and/or sonosensitizer compounds that collect in hyperproliferative tissue are provided. | 2009-11-05 |
20090275549 | USE OF PICOPLATIN TO TREAT COLORECTAL CANCER - The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. | 2009-11-05 |
20090275550 | Pyridyl Amide T-Type Calcium Channel Antagonists - The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2009-11-05 |
20090275551 | Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins - The present disclosure relates to method of using fluvastatin, alone or in combination with ezetimibe, be used to (1) lower cholesterol level, (2) treat hypercholesterolemia, (3) treat mixed dyslipidemia and/or (4) inhibit cholesterol biosynthesis in patients who experienced muscle-related side effects (MRSE). The present disclosure also relates to a pharmaceutical composition comprising ezetimibe and fluvastatin. | 2009-11-05 |
20090275552 | Therapy for Treating Resistant Bacterial Infections - The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum β-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have better control over the therapy; achieve reduced hospital stay and adjuvant step down therapy so as to avoid recrudescence. In particular, the therapy includes antibacterial combination of cefepime with sulbactam via parenteral route, followed by oral third generation cephalosporin with a suitable β lactamase inhibitor. | 2009-11-05 |
20090275553 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage. | 2009-11-05 |
20090275554 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF - The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. | 2009-11-05 |
20090275555 | Substituted indole ligands for the ORL-1 receptor - New ligands for the ORL-1 receptor are described, useful for antagonising the activity of said receptors in a patient in need thereof, and for preventing and treating illnesses dependent on the activation of this receptor. The new compounds conform to structural formula (I) wherein R1, R2, R3, R4 are further defined in the description. | 2009-11-05 |
20090275556 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity - The present invention provides compounds of general formula I: | 2009-11-05 |
20090275557 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes - The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists. | 2009-11-05 |
20090275558 | SUBSTITUTED SULFONAMIDE COMPOUNDS - Substituted sulfonamide compounds corresponding to formula I | 2009-11-05 |
20090275559 | Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina - The present invention relates to formulations of anti-hypertensive drugs. The present invention includes a modified-release formulation of diltiazem hydrochloride that is suitable for once-daily use and which provides delivery of drug either in the early morning hours, or overnight, so as to blunt the natural rise in blood pressure (BP) and heart rate (HR) in the morning and to reduce the slope of the increase in BP in patients with elevated BP (hypertension). | 2009-11-05 |
20090275560 | ORGANIC COMPOUNDS - The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by | 2009-11-05 |
20090275561 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2009-11-05 |
20090275562 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION - A reduction in the side effects of treating with an agent having combined 5HT | 2009-11-05 |
20090275563 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy - Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor. | 2009-11-05 |
20090275564 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Aminopurine Compounds having the following structure: | 2009-11-05 |
20090275565 | Substituted aralkyl derivatives - The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation. | 2009-11-05 |
20090275566 | BACE INHIBITORS - The present invention provides BACE inhibitors of Formula I: | 2009-11-05 |
20090275567 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION - Compounds of formula (I): | 2009-11-05 |
20090275568 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF - The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) | 2009-11-05 |
20090275569 | Benzotriazine Inhibitors of Kinases - The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases. | 2009-11-05 |
20090275570 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS - The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer. | 2009-11-05 |
20090275571 | MORPHOLINYL AND PYRROLIDINYL ANALOGS - The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II. | 2009-11-05 |
20090275572 | FAB I INHIBITORS - Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections. | 2009-11-05 |
20090275573 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors - Compounds of formula | 2009-11-05 |
20090275574 | NOVEL COMPOUNDS-300 - Compounds of Formula I, or pharmaceutically acceptable salts thereof: | 2009-11-05 |
20090275575 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE - Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells. | 2009-11-05 |
20090275576 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE - A subject-matter of the invention is the compounds of general formula (I) | 2009-11-05 |
20090275577 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS - Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents. | 2009-11-05 |
20090275578 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators - The present invention is directed to compounds of formula I: | 2009-11-05 |
20090275579 | 3-SPIROINDOLIN-2-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The subject of the present invention is a compound of formula (I): | 2009-11-05 |
20090275580 | 3-SPIROINDOLIN-2-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The subject of the present invention is a compound of formula (I): | 2009-11-05 |
20090275581 | RENIN INHIBITORS - Disclosed are compounds according to Formula I: | 2009-11-05 |
20090275582 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases - The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. | 2009-11-05 |
20090275583 | ANTIVIRAL COMPOUNDS AND USE THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2009-11-05 |
20090275584 | BIOCIDAL COMBINATIONS COMPRISING IMAZALIL - The present invention relates to combinations of imazalil, or a salt thereof, and a biocidal compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more biocidal compounds selected from tolylfluanid, dichlofluanid, OIT, DCOIT, terbutryn, chlorothalonil, hexamin and 1,2-benzisothiazolone in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like. | 2009-11-05 |
20090275585 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition - Novel compound having the following formula: | 2009-11-05 |
20090275586 | HETEROCYCLIC INHIBITORS OF PDE4 - The present invention is directed to potent and selective heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory diseases and other diseases in which PDE4 or one of its isoforms may play a role. | 2009-11-05 |
20090275587 | METHODS OF TREATING ISCHEMIC RELATED CONDITIONS - The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia. | 2009-11-05 |
20090275588 | NOVEL SULFONAMIDE COMPOUNDS - The invention relates to novel sulfonamide compounds and their use as orexin receptor antagonists. | 2009-11-05 |
20090275589 | Pyridazine Compound and Use Thereof - A pyridazine compound of the formula: | 2009-11-05 |
20090275590 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES - Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) | 2009-11-05 |
20090275591 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR - The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R | 2009-11-05 |
20090275592 | Heterocyclic modulators of PKB - The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. | 2009-11-05 |
20090275593 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors - The invention relates to 3-substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidine compounds, their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds. | 2009-11-05 |
20090275594 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS - The present invention is directed to novel 3-hydrazone piperazinyl rifamycin derivatives, pharmaceutical compositions containing them and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes. | 2009-11-05 |
20090275595 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE - There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof. There is also to provide a method for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion, comprising simultaneously administering, or separately administering with interval of time an effective amount of the compound 1, its pharmaceutically acceptable salt or a hydrate thereof and an effective amount of Pitavastatin to a patient in need thereof. | 2009-11-05 |
20090275596 | Treatment of Neurodegenerative Disorders with Thiourea Compounds - A method for treating a neurodegenerative disorder. The method includes administering to a subject in need thereof an effective amount of one or more thiourea compounds of formula (I) or (II): | 2009-11-05 |
20090275597 | METHODS OF TREATING CNS DISORDERS - The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists. | 2009-11-05 |
20090275598 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: | 2009-11-05 |
20090275599 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS - A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects. | 2009-11-05 |
20090275600 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators. | 2009-11-05 |
20090275601 | Novel Pyriproxyfen Compositions - New pesticidal compositions comprising pyriproxyfen and methyl esters of C | 2009-11-05 |
20090275602 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I | 2009-11-05 |
20090275603 | NF- kB Inhibitors And Uses Thereof - A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants. | 2009-11-05 |
20090275604 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 2009-11-05 |
20090275605 | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease - The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,11b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof. | 2009-11-05 |
20090275606 | Heterocyclic Compounds as MEK Inhibitors - The present invention relates to compounds of formula I | 2009-11-05 |